Condition (MeSH)
Cystadenocarcinoma, Mucinous
ClinicalTrials.gov lists 2 trials for Cystadenocarcinoma, Mucinous or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with Cystadenocarcinoma, Mucinous itself; the rest are tagged with a narrower condition beneath it.
When did Cystadenocarcinoma, Mucinous trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2017 | 1 |
| 2009 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cystadenocarcinoma, Mucinous trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Not applicable | 1 |
How many Cystadenocarcinoma, Mucinous trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Active, not recruiting | 1 |
| Completed | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cystadenocarcinoma, Mucinous trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 1 |
Which publications cover Cystadenocarcinoma, Mucinous? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Suboptimal accuracy of carcinoembryonic antigen in differentiation of mucinous and nonmucinous pancreatic cysts: results of a large multicenter study. | Gastrointestinal endoscopy | 2015 | Yes |
| Is MRI a useful tool to distinguish between serous and mucinous borderline ovarian tumours? | Clinical radiology | 2013 | Yes |
| Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 1997 | Yes |
| European experts consensus statement on cystic tumours of the pancreas. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2013 | No |
| Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. | International journal of cancer | 2005 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.